IQ-AI Limited "Gad Free" Imaging - One Step Closer (0670Y)
September 04 2020 - 3:03AM
UK Regulatory
TIDMIQAI
RNS Number : 0670Y
IQ-AI Limited
04 September 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
"Gad Free" Imaging - One Step Closer
The development team at Imaging Biometrics ("IB"), the wholly
owned subsidiary of IQ-AI, Ltd, achieved a significant milestone in
the development of a zero percent Gadolinium-based contrast agents
("GBCA") approach. The team's initial goal is focused on the
generation of a brain image equivalent to a post-contrast image
using information provided from anatomical and functional images
acquired without any administration of exogenous contrast material.
Led by Dr. Jay Urbain PhD, a leading Artificial Intelligence (AI)
expert, a Deep Learning (DL) algorithm was developed that uses
T1-weighted, T2, and fluid attenuation inverse recovery (FLAIR) as
inputs. These inputs are common MR sequences collected as part of
routine brain scans. The DL model ("Model") then extracts
feature-derived information to create images analogous to
post-contrast (T1+C) images.
This Model is now ready to begin the next phase of development.
This phase includes comparing the algorithm's output to "ground
truth", or images acquired with GBCA, on a much larger dataset from
multiple scanner vendors and field strengths.
Along with the longstanding toxicity concerns related to
Gadolinium-based ("Gd") retention in the body, recent reports
identified increased Gd levels are being detected in rivers, in
lakes, and even in sodas at fast food chains. While the long-term
use of GBCAs as a paramagnetic material for medical resonance (MR)
imaging are not known and the benefits of scanning with GBCAs are
well acknowledged, there is a continued effort by multiple groups
to reduce and/or eliminate GBCAs in medical imaging. This effort,
driven in part by the accessibility of AI networks and computing
horsepower through the likes of Google and AWS (Amazon Web
Services), continues at Imaging Biometrics (IB).
GBCAs are fundamental to imaging. Since obtaining approval in
1988, nearly half a billion GBCAs have been administered.
Successfully translating this technology to routine clinical use
represents a significant disruption to current practice and, for
IQ-AI, the pipeline for distributing a validated solution is
already well established.
In October of 2018, IQ-AI announced that it had filed for a
patent to the United States Patent and Trademark Office. This
application is still pending review.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics , LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STREAPNLEEEEEEA
(END) Dow Jones Newswires
September 04, 2020 04:03 ET (08:03 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024